Shanghai RAAS Blood Products' controlling shareholder Haiyingkang has completed its additional purchase and has increased its stake by a total of 1.09%.

Shanghai RAAS Blood Products (002252.SZ) announced that the shareholding plan of the company's controlling shareholder, Haiying Kang, has been completed. Haiying Kang has accumulated 72.43 million shares of the company through centralized bidding, accounting for 1.09% of the total share capital of the company. The total amount of the shareholding is approximately 497 million yuan (excluding transaction costs).